for David, call. and the you, you, everyone joining Thank thank
on platform the second highlight to and programs. As for quarter takeaways provide my usual, period, I remarks arrange key will and our subsequent updates the
update INKmune pass reviewing upcoming David with on XPro back before an and results financial will start to our and milestones. new developments provide I I by to discuss it and
We move will to Q&A. then
and of blinded with increasing randomized Alzheimer's disease remained the trial our inflammation second patients focus with early of trial. footprint enrollment the that During patients in quarter, into the primary geographic Phase X
We global. are going
regulatory authorities is from the been Expanding footprint jurisdictions. this has the geographic some hangover in staffing problems COVID era. I at believe slowed by a
one can just For days required you their the XXX has past problem. do nothing by -- the with time about But requests law. a it and there's We instance, response needed. deal as answer country is
One-third is continues Label of continue on Enrollment entering to accelerate, Extension received treatment and to Extension an XPro Phase bites opt see placebo the Open to opportunity or that patients X Open XPro. now been data. apple, Label and to additional open-label to patients OLE we the finish I capture if program. encouraged under provides the are the should extension you two be have the may. able trial respond the the to at We have that remind patients I they've therapy. not These
for who efficacy Patients partners trial, XPro the important drug clinical follow-up, who the on issues received safety long-term on for and authorities. investors, two-thirds drug the during and we'll provides the data had and the potential active regulatory teams, been company, continue
hold the process with nearing end, its end clinical conditions is and This FDA track on to hope. remain to the the frustrating lift before long we Finally, manufacturing meet we the year. necessary of the
patients data with Conference annual release completed from Alzheimer's with Association The filled just AD. promise and The of Donanemab International early Lilly's was the both promise was in pragmatism. study
X there different of large are performed now Phase studies antibodies. anti-amyloid release the data, that three With with
and trial the of will similarities. my will and The three marketing their results. Put patients hat, in studies showed drug therapies see in companies although respective consistent commercial see safety. differences the way, staffs the another clinical efficacy Clinicians wearing three
confirmed that they there effect. by treating was clinical It there multi-day survey disease. the seen reflected Alzheimer’s in amyloid. plenty targeting for the was pragmatisms more. Alzheimer's That improvement But room disease There professionals. for need is was additional is in no the drugs their palpable opinion, a A class drugs by want
The and that drugs list. and top not clinical tau amyloid, first, targeting teams and do the outcomes on that additional improve want neuroinflammation are target three clinical of experts things: that drugs
there Second, is can The should for to best drugs easily early identify blood help desire for a and treated is process in disease the when better patient the patients what they biomarkers tests. obtained receive. be select preference
results require no anti-amyloid therapy a complex serious treatment and one topic Alzheimer's Alzheimer's of trials satisfied expect disease and of We combination with therapy. combination has a disease with with modern complex monotherapy difference should diseases become No the often Finally, is discussion. is the medicine disease.
rare An much the to the There after do interesting amyloid gone. is with scratching at head what patients meeting. head was did problem about
the they amyloid the with cognitive fact, for is the stopped patients show Lilly trial drug a In but gone, the solve this continue donanemab, decline. problem. to there need is once progressive Clearly, something to
positioned decline fulfill problem. new to amyloid therapy, cognitive with believe well is Like this without we combination XPro
our the trying scratching understand into the and company be may overall were XPro I'll to technical attempt gray bit the posters presented heads these on elements Amsterdam. microstructure and dense our effects data complicated highly data in integrate meeting the program for little of Some data you. at on to The a
micro of in that whole is affect elements Alzheimer's brain. brain, is structural XPro where the both gray presented that have on -- with matter, benefits is of white XPro we matter the the on white on Alzheimer's. structural has positively extensively presented in data most green XPro Because elements And have the gray show matter, normalize severe. asked, matter. both gray That the in does matter brain hematopathology what pathology the of and these white some and areas patients white We well, in micro treatment helps about the
the that have we So you the is shown and aging destructive XPro. and control brain remains of to with neuro XPro shown neuroinflammation, cognitive repair already these myelin. impact occurs of changes the changes remodeling biology of on synaptic suggest function. that These data What be information neurodegeneration of when
shall of with dose had treated eight four XPro or XPro Phase therapy. In we patients cognition nine stable improved X on say, the open-label trial,
patients We But question that Phase our ongoing able the we've Alzheimer's in cognition and trial. have we until completed this flatline with be disease in won't will answer to X really been neuroinflammation. vocal belief XPro
We TNF our treatment dominant platform for in for using Dystrophy have signaled the Duchene negative DMD. the DN-TNF the Muscular of interest or
TNF. As the DMD speak. our highlighted allows asset leaving so in shelf, treating a that wholly owned the of business January, subsidiary us our the disease to treatment separate will property activities to to dominant without Alzheimer's business we focus development partnering established structure that core intellectual DNXX, and on for hold mission is negative valuable on This with a facilitate
destruction. Our muscle the for does data. more. clear. must in on is DMD fiber based decrease interesting The is A and therapy confidence most The ticket and and muscle treatment DMD attribute regeneration. fiber preclinical entry inflammation improves is novel DN-TNF that DN-TNF decrease that into
seen regeneration the muscle not has any may biologic been course gene boys. knowledge, change regeneration the molecule our To or disease therapy in fiber these of muscle A in therapies. small promotes fiber that
care As of preclinical the of studies part to DN-TNF advantage we to of effort, understand standard are compared therapy. molecular therapy corticosteroid performing the
potential working are find hard a partner We promising asset. this for to
INKmune platform. the to DN-TNF from Moving
it's decision from May recall letter. is for hematologic Phase This used. mCRPC, tumors. days FDA the clinical to the pivot an Prostate trial treatment Cancer, using INKmune with in or simple the e-mail or safe our received You Actually, X/X FDA we these that from that common to INKmune to treating the more proceed phrase Castration-Resistant to formalized solid is diseases e-mail metastatic using treat is
do NK INKmune biology was for undergo TME. NK NK and on The primed this treatment that pivot of target for to carefully choice unique in solid genetically cells metastatic the The tumor prostate as based cytokine these hypoxic changes primed allow our in critical the knowledge, primed successful the undergo are was immunologically cells To NK that cells or our considered. function of castrate-resistant decision cells, first cell. modified INKmune cancer not NK tumors. hostile changes
INKmune not resting tumor the we or not six change cancer cancer can cells finally, believe Prostate the prostate that decreasing last well-established of have over the robust And cancer. tumors cancer patient. revolution few in to but is from if immunotherapy determine that cell castrate-resistant We allow years. kill is NK specimens five are NK that cells burden do biomarkers Prostate us is benefited a cancer one that. have metastatic the the infiltrates,
cancer castrate-resistant the of disease condition expectations profile the therapy. with metastatic prostate metastatic say, a Finally, active, sedentary. with INKmune, ranges castrate-resistant live very cancer a men with for life. outpatient This their from to pre-medication, of long as given cytokine who of prostate high quality time and without the often an health or well difficult-to-use value normal aligns with therapeutic let's men is need cytotoxic
of Immunologic enroll one first XX outpatient will by how the to patient Immunologic that in the trial we measured be by present during memory-like the will six the at take US, a therapeutic novel NK design six The is in Patients Bayesian of increase patient minimum trial. end is blood a doses the efficacy and will month long cells year. in expected circulation. to INKmune three of plan The trial enroll be will are measured. the efficacy and these in the receive of sites cells men. and the place
bone burden PMSA-PET traditional expect Therapeutic including tumor be cancer PSA, the include response prostate DNA. to correlate scan scan tumor efficacy circulating biomarkers as which and INKmune effects. or of biomarkers scans and as this novel tumor well using to with therapeutic tumor will CT Blood We of burden,
risk one activation. complete the showed and the Three remains three quality is other received an died great four ongoing We XX evidence continue that trial Of it to transplant, tolerated. far in so transplant. high show received enjoyed to well a were patients, AML while the therapy dose treat have post-treatment patients patients the waiting trial. four of bridged having of and of the patients NK Phase four actually no has life. with That's Two regimen, the patients, Laurel results for patients improved in months I patient cell one MDS alive
third site in Athens. We've clinical opened a
August. recruitment the been been clinical have patients of Greek patient in trial. barriers first planned end treatment is the There major The two to has identified Laurel and for of
original first the and COVID-XX. The those was and sites persist. really suffered Health The Service COVID under UK's National all in and UK are service dislocations the
cohort. first experience use the enrollment can we the second conservative, problems. The be more criteria is the problem we enrollment solve enrollment to made some that will believe With this criteria enrollment of for liberal, related
INKmune, remains on offer one effective in unique and platforms their moving treat to committed therapeutic silos. vision commercialization. Both of options than execute its more disease company The XPro to towards therapeutic
about building value. to both difference the at are shareholder the excited and while are a platforms prospects working make hard of We bedside,
Moss, review financial David to to this certain return items I
